USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
MATTEK CORPORATION
Address:
200 HOMER AVE
ASHLAND, MA
Phone:
N/A
URL:
N/A
EIN:
42877744
DUNS:
147365936
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $5,140,363.00 40
SBIR Phase II $14,408,360.00 18

Award List:

MODIFIED SURFACES FOR CHEMICALLY DEFINED CELL CULTURE

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$15,760.00
Agency:
HHS
Principal Investigator:
Mitchell Klausner
Abstract:
The primary goal of this research is the development of novel plastics on which to culture cells in serum-free media. currently, biological attachment aids must be used for anchorage-dependent cells to attach and grow normally inthe absence of serum. low-temperature gas plasma techniques will be… More

BIOCOMPATIBLE MEMBRANES FOR LONG-TERM IMPLANTATION IN THE STOMACH

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$49,999.00
Agency:
HHS
Principal Investigator:
Mitchell Klausner
Abstract:
Although microdialysis has been very useful for the acute monitoring of the biochemical mechanisms of the stomach and alimentary tract, chronic studies have not been as successful. hollow-fiber membranes (hfms) implanted for extended periods in the stomach walls of laboratory animals have caused… More

IMPROVED MICROPOROUS MEMBRANES FOR MAMMALIAN CELL CULTURE

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$45,785.00
Agency:
HHS
Principal Investigator:
Mitchell Klausner
Abstract:
N/a

IMPROVED MICROPOROUS MEMBRANES FOR MAMMALIAN CELL CULTURE

Award Year / Program / Phase:
1991 / SBIR / Phase II
Award Amount:
$484,594.00
Agency:
HHS
Principal Investigator:
Mitchell Klausner
Abstract:
Microporous membranes offer researchers many experimental advantages over other cell culture methods. in addition, cells cultured on such membranes exhibit enhanced differentiation and many other properties that closely resemble those observed in vivo. however, currently the use of such membranes is… More

CELL CULTURE SURFACES FOR BONE RESEARCH

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Klausner, Mitchell , Principal Investigator
Abstract:
Surfaces for cell culture are used in many areas of bone research. the study of osteoblast cell culture is currently used to examine the molecular mechanisms leading to bone growth, morphology and mineralization. understanding of these molecular mechanisms gives insight into the origins and… More

In Vitro Model for Dermal Irritation

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Joseph Kubilus
Abstract:
In order to protect the general public from a broad variety of potentially harmful products and chemicals, toxicologic testing for dermal irritancy is routinely performed using laboratory animals. However, the use of animals and their maintenance is becoming increasingly costly. Animal testing… More

Cultured Corneal Epithelium-Draize Test Replacement

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$38,821.00
Agency:
HHS
Principal Investigator:
Mitchell Klausner
Abstract:
N/a

Organotypic Skin Cultures with Improved Barriers

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Mitchell Klausner
Abstract:
N/a

Organotypic Skin Model Containing Melanocytes

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$75,000.00
Agency:
HHS
Principal Investigator:
Mitchell Klausner
Abstract:
Many highly differentiated in vitro epidermal and dermal/epidermal skin models have beendeveloped which are useful for several reasons: 1) transdermal drug delivery systems, 2) skintransplantation, and 3) dermal irritancy testing. For the most part, these models incorporate epidermalkeratinocytes… More

Cultured Corneal Epithelium-Draize Test Replacement

Award Year / Program / Phase:
1995 / SBIR / Phase II
Award Amount:
$604,335.00
Agency:
HHS
Principal Investigator:
Mitchell Klausner
Abstract:
One of the most controversial toxicology tests currently performed is the Draize rabbit eye irritancy test. In addition to the moral outcry against the procedure, the Draize test has been criticized due to the high degree of inter- and intra-laboratory variability, its lack of objectivity, and the… More

Organotypic Skin Cultures with Improved Barriers

Award Year / Program / Phase:
1997 / SBIR / Phase II
Award Amount:
$749,665.00
Agency:
HHS
Principal Investigator:
Mitchell Klausner
Abstract:
Many highly differentiated in vitro epidermal and dermal/epidermal skin models are being developed which would be extremely useful for 1) transdermal drug delivery systems, 2) skin transplantation, and 3) dermal toxicity testing. However, none of the current models accurately reproduce the barrier… More

RECONSTRUCTED SKIN MODEL CONTAINING LANGERHANS CELLS

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Klausner, mitchell
Abstract:
N/a

DIFFERENTIATED AIRWAY EPITHELIAL CULTURES

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Klausner, mitchell
Abstract:
N/a

IMMORTALIZED HUMAN LANGERHANS CELLS

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Klausner, Mitchell
Abstract:
N/a

N/A

Award Year / Program / Phase:
1999 / SBIR / Phase II
Award Amount:
$642,823.00
Agency:
HHS
Principal Investigator:
Klausner mitchell
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$285,409.00
Agency:
HHS
Principal Investigator:
Mitchell Klausner
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Mitchell Klausner
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Patrick J. Hayden
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$70,000.00
Agency / Branch:
DOD / CBD
Principal Investigator:
Patrick Hayden, Senior Cell Biologist
Abstract:
N/a

N/A

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

Development of a Vaccine for the Treatment and/or Prevention of Cancer

Award Year / Program / Phase:
2001 / SBIR / Phase II
Award Amount:
$780,000.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Seyoum Ayehunie, Senior Cell Biologist
Abstract:
Prostate cancer is the most common non-skin malignancy in the United States. With the exception of lung cancer, it is the leading cause of death in men in the country. By age 80, the risk of developing prostate cancer is estimated to be 1 in 7. Despiteincreased public awareness, regular… More

Development of a Vaccine for the Treatment and/or Prevention of Cancer

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$70,000.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Seyoum Ayehunie, Senior Cell Biologist
Abstract:
Prostate cancer is the most common non-skin malignancy in the United States. With the exception of lung cancer, it is the leading cause of death in men in the country. By age 80, the risk of developing prostate cancer is estimated to be 1 in 7. Despiteincreased public awareness, regular… More

High-Throughput Screening of Therapeutics

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Patrick J. Hayden
Abstract:
N/a

High-Throughput Screening of Therapeutics

Award Year / Program / Phase:
2001 / SBIR / Phase II
Award Amount:
$337,976.00
Agency:
HHS
Principal Investigator:
Patrick J. Hayden
Abstract:
N/a

Eyesafe, Multi-function Coherent Doppler Lidar for Stand-Off Bioaerosol Discrimination

Award Year / Program / Phase:
2001 / SBIR / Phase II
Award Amount:
$730,000.00
Agency / Branch:
DOD / CBD
Principal Investigator:
Patrick Hayden, Senior Cell Biologist
Abstract:
Chemical warfare agents such as bis-(b-chloroethyl) sulfide (HD) pose a significant threat to U.S. military and civilian populations. Exposure of skin to HD causes burn-like symptoms such as erythema, edema and severe incapacitating vesication(blistering). To combat this threat, prophylactic and/or… More

Immortized Human Langerhans Cells

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Seyoum Ayehunie
Abstract:
DESCRIPTION(provided by applicant): During Phase I, human Langerhans cell (LC) lines were obtained by transfecting or infecting LC progenitor cells derived from peripheral blood and bone marrow. The best cell lines were transformed with a well-known viral oncogene and could be… More

Immortized Human Langerhans Cells

Award Year / Program / Phase:
2001 / SBIR / Phase II
Award Amount:
$427,586.00
Agency:
HHS
Principal Investigator:
Seyoum Ayehunie
Abstract:
DESCRIPTION(provided by applicant): During Phase I, human Langerhans cell (LC) lines were obtained by transfecting or infecting LC progenitor cells derived from peripheral blood and bone marrow. The best cell lines were transformed with a well-known viral oncogene and could be… More

Eyesafe, Multi-function Coherent Doppler Lidar for Stand-Off Bioaerosol Discrimination

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$0.00
Agency / Branch:
DOD / CBD
Principal Investigator:
Patrick Hayden, Senior Cell Biologist
Abstract:
Chemical warfare agents such as bis-(b-chloroethyl) sulfide (HD) pose a significant threat to U.S. military and civilian populations. Exposure of skin to HD causes burn-like symptoms such as erythema, edema and severe incapacitating vesication(blistering). To combat this threat, prophylactic and/or… More

IN VITRO MODEL FOR MEASURING SUNSCREEN PROTECTION

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Patrick J. Hayden
Abstract:
DESCRIPTION: (Verbatim) - Excessive exposure to solar radiation results in erythema (sunburn) and has been linked to premature skin aging, immunosuppression and skin cancer. Despite greater awareness by the public of the harmful effects of exposure to sunlight… More

HIGHLY DIFFERENTIATED TISSUE CULTURE MODELS OF MELANOMA

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$152,197.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): With the exception of lung cancer in women, the incidence of cutaneous melanoma (CM) is increasing faster than any other cancer. Current estimates are that one of every 75 individuals in the US will contract CM during his or her lifetime. The various stages of… More

RECONSTRUCTION OF SKIN MODEL CONTAINING LANGERHANS CELLS

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Phase I research demonstrated that a Langerhans cell (LC) containing model of the epidermis is feasible. LC progenitor cells were harvested from peripheral or cord blood samples, cryopreserved, and matured using cytokines into the LC specific CD1a+ phenotype. … More

RECONSTRUCTION OF SKIN MODEL CONTAINING LANGERHANS CELLS

Award Year / Program / Phase:
2002 / SBIR / Phase II
Award Amount:
$830,929.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Phase I research demonstrated that a Langerhans cell (LC) containing model of the epidermis is feasible. LC progenitor cells were harvested from peripheral or cord blood samples, cryopreserved, and matured using cytokines into the LC specific CD1a+ phenotype. … More

IN VITRO SKIN MODEL FOR PERCUTANEOUS ABSORPTION STUDIES

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$181,352.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by the applicant): The ability to produce skin in vitro with barrier properties equivalent to those of native epidermis remains a much sought after goal. The current proposal will utilize a number of recent improvements in the organotypic culture of… More

HUMAN TISSUE MODEL FOR HETEROSEXUAL HIV TRANSMISSION

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Abstract:
Phase I research adapted primary culture methods to obtain a reliable source of normal ectocervico-vaginal (ECV) epithelial and Langerhans precursor (LP) cells. Tissue culture conditions were developed to induce these cells to differentiate into a three-dimensional, organotypic tissue.… More

HUMAN TISSUE MODEL FOR HETEROSEXUAL HIV TRANSMISSION

Award Year / Program / Phase:
2002 / SBIR / Phase II
Award Amount:
$1,073,017.00
Agency:
HHS
Principal Investigator:
Abstract:
Phase I research adapted primary culture methods to obtain a reliable source of normal ectocervico-vaginal (ECV) epithelial and Langerhans precursor (LP) cells. Tissue culture conditions were developed to induce these cells to differentiate into a three-dimensional, organotypic tissue.… More

In Vitro Culture Model of the Human Blood-Brain Barrier

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$369,087.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Solute distribution between blood and brain is strictly regulated by the blood-brain barrier (BBB) at brain capillary endothelial cells. While the BBB performs an important function in keeping unnecessary or harmful molecules from the brain, it poses a… More

Reconstructed Human Oral Tissues

Award Year / Program / Phase:
2003 / SBIR / Phase II
Award Amount:
$874,671.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Phase I research adapted primary culture methods to obtain a reliable source of normal human buccal epithelial (NHBE) cells. Tissue culture methods were developed to induce the NHBE cells to differentiate into a three-dimensional organotypic tissue.… More

Reconstructed Human Oral Tissues

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Phase I research adapted primary culture methods to obtain a reliable source of normal human buccal epithelial (NHBE) cells. Tissue culture methods were developed to induce the NHBE cells to differentiate into a three-dimensional organotypic tissue.… More

In Vitro Model of the Human Alveolar Epithelium

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$249,404.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The distal airways possess a variety of features, which make them an attractive site for systemic delivery of therapeutics. These include a very thin epithelium, large surface area, avoidance of hepatic first pass metabolism and extensive vascularization.… More

In Vitro Assay For Chemical Allergens

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$206,494.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Allergic contact dermatitis (ACD) is one of the most common and costly health problems in industrialized countries. Currently more than 100,000 chemicals are in commercial use and another 2,000 new chemicals and numerous new-product formulations are tested or… More

Validation of an In Vitro Human Airway Model

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$199,903.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): A commercially available in vitro model of human conducting airways (EpiAirway) has been developed and utilized for a variety of basic research and industry drug delivery applications. However, the model has not been formally validated for toxicology applications… More

Pre-validation of Tissue Specific Micronucleus Assay for Genotoxicity Testing

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$207,730.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Safety assessment of any new product for human use requires genotoxicity testing to insure that the product is not carcinogenic. Current genotoxicity assays are based on bacterial or non-human cell systems. Such tests are sensitive but give very low specificity… More

In Vitro Tissue Model of Psoriasis

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$210,982.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Psoriasis is a chronic inflammatory and proliferative skin disease that affects 2-3% of the population in Western countries and an estimated 80 million people worldwide. The disease causes disfiguration in 10- 30% of cases and arthiritis in 10-15% of patients.… More

Validation of a Human In Vitro Vaginal Irritation Test

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$212,292.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Exposure of female reproductive tract to the various chemical agents contained within spermicides, medicaments, microbicides, feminine hygiene and other vaginal care products (VCP) can cause inflammation or tissue damag e and thus endanger the health of women.… More

Tissue Engineered In Vitro Human Airway Models of Asthma and COPD

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$215,533.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Asthma and chronic obstructive pulmonary disease (COPD) are the two leading chronic respiratory diseases in the US. However, reliable in vitro human models are not widely available to pharmaceutical researchers who are attempting to understand asthma and COPD… More

Validation of Organotypic Vaginal Tissue Based Assay for Endocrine Disruptors

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$211,817.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Environmental or intentional exposure to a broad variety of chemical agents can alter normal endocrine function. The effects of these endocrine disruptors (ED) can have serious health implications including deleteriou s effects to reproductive capacity, fetal… More

In Vitro Assay for Chemical Allergens

Award Year / Program / Phase:
2007 / SBIR / Phase II
Award Amount:
$1,127,441.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Allergic contact dermatitis (ACD) is one of the most common and costly health problems in industrialized countries. Currently, more than 100,000 chemicals are in commercial use and another 2,000 new chemicals and numero us new-product formulations are tested or… More

Globally Harmonized In Vitro Skin Irritation Assay

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$255,954.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant):PUBLIC HEALTH RELEVANCE Determination of skin irritation potential is an international regulatory requirement for hazard identification/assessment of chemicals, and is important in establishing procedures for the safe ha ndling, packaging, labeling and transport… More

Human Corneal Model for Ocular Irritation Assay

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$233,250.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Replacement of the Draize rabbit eye test for ocular irritancy testing remains an elusive goal. Although monolayer cultures and stratified corneal epithelial tissues have been developed and are useful as initial screens for ocular irritancy, they are not capable… More

In Vitro Assay to Determine Skin Corrosivity Packing Groups

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$244,444.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): US Department of Transportation and international regulations require testing of all chemicals for skin corrosivity, which is defined as destruction of human skin at the site of contact. For safe handling and transporta tion purposes, each corrosive is assigned a… More

Validation of a Human In Vitro Vaginal Irritation Test

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$1,205,751.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): During Phase 1 research, the effects of 6 model test materials on a highly differentiated vaginal- ectocervical (VEC) tissue model were studied. Effects on tissue viability, structure, barrier function, and inflammatory cytokine release were monitored. Many of… More

Reconstructed Skin Micronucleus Genotoxicity Assay

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$819,104.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): As part of a standard toxicological evaluation, all new products must be tested to insure they are not genotoxic. Animal tests are available but European legislation that takes effect in 2009 will ban animal testing. T his legislation will affect almost all… More

Genetically modifed tissue engineered in vitro human models

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$221,236.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of the current proposal is to apply state of the art gene modification technology including lentiviral delivery systems and RNA interference technology to commercially available tissue engineered human in vitro models. These models will consist of… More

In Vitro Human Tissue Model for Intravaginal Drug Delivery

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$267,914.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Due to the avoidance of first-pass hepatic metabolism and gastrointestinal irritation, intravaginal administration is an attractive option for systemic delivery of drugs. Current vaginal drug delivery studies are primar ily performed using the FDA-accepted rabbit… More

Validation of an In Vitro Human Airway Model

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$835,982.00
Agency:
HHS
Principal Investigator:
Patrick J. Hayden – 508-881-6771
Abstract:
DESCRIPTION (provided by applicant): Hazard assessment, including evaluation of acute inhalation toxicity potential, is a mandatory international regulatory requirement for chemicals utilized in international commerce. Acute inhalation toxicity or irritation potential is an important consideration… More

Validation of Human Vaginal Tissue Assay for Endocrine Disruptors

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$993,515.00
Agency:
HHS
Principal Investigator:
Seyoum Ayehunie – 508-881-6771
Abstract:
DESCRIPTION (provided by applicant): Environmental or occupational exposure to a broad variety of chemical agents can alter normal endocrine function. The effects of these endocrine disruptors (ED) can have serious health implications including deleterious effects to reproductive capacity, fetal… More

Human Corneal Model for Ocular Irritation Assay

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$924,517.00
Agency:
HHS
Principal Investigator:
Yulia Kaluzhny – 508-881-6771
Abstract:
DESCRIPTION (provided by applicant): Replacement of the Draize rabbit eye test for ocular irritancy testing remains an elusive goal. Many believe a corneal full thickness (CFT) model is necessary to completely model the interaction of exogenous chemicals with human cornea. During Phase 1, human… More

Genetically modified tissue engineered in vitro human models

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$966,454.00
Agency:
HHS
Principal Investigator:
Patrick J. Hayden – 508-881-6771
Abstract:
DESCRIPTION (provided by applicant): The goal of the current proposal is to apply state-of-the-art gene modification technology, including lentiviral delivery systems and RNA interference (RNAi) technology, to produce commercially available tissue engineered in vitro human models with advanced… More